Skip to main content
Indietro

Blood: Hemostasis, Clotting, and Transfusion – Study Notes for Anatomy & Physiology

Guida di studio - Note intelligenti

Appunti personalizzati basati sui tuoi materiali, ampliati con definizioni chiave, esempi e contesto.

Blood: Hemostasis, Clotting, and Transfusion

Overview

This section covers the physiology of blood, focusing on hemostasis, coagulation, clot retraction and fibrinolysis, disorders of hemostasis, and blood transfusion principles. Understanding these topics is essential for grasping the mechanisms that maintain vascular integrity and the clinical implications of blood loss and transfusion.

Hemostasis

Coagulation

Hemostasis is the process that stops bleeding after vascular injury. Coagulation is a critical phase where blood is transformed from a liquid to a gel, reinforcing the platelet plug with fibrin threads to seal larger vessel breaks.

  • Clotting Factors (Procoagulants): Mostly plasma proteins, numbered I to XIII in order of discovery. Vitamin K is required to synthesize four of these factors.

  • Phases of Coagulation:

    1. Phase 1: Formation of Prothrombin Activator via two pathways:

      • Intrinsic Pathway: Clotting of blood outside the body (e.g., in a test tube) or in slightly damaged vessels. Triggered by negatively charged surfaces such as collagen.

      • Extrinsic Pathway: Clotting in response to tissue damage, initiated by release of tissue factor (TF). Faster than intrinsic pathway.

      Both pathways converge at activation of Factor X, which complexes with Ca2+, PF3 (platelet factor 3), and Factor V to form prothrombin activator.

    2. Phase 2: Prothrombin activator catalyzes transformation of prothrombin to active enzyme thrombin.

    3. Phase 3: Thrombin converts soluble fibrinogen to insoluble fibrin, forming a mesh that traps blood cells. Thrombin (with Ca2+) activates Factor XIII (fibrin stabilizing factor), which cross-links fibrin and strengthens the clot.

  • Equation:

  • Example: Rapid formation of a blood clot after a cut to the skin.

Blood Clotting Factors (Procoagulants)

Blood clotting involves a cascade of plasma proteins, each with a specific role in the process.

Factor Number

Factor Name

Source

Main Function

I

Fibrinogen

Plasma protein

Forms fibrin threads of clot

II

Prothrombin

Plasma protein

Converted to thrombin

III

Tissue factor (TF)

Plasma membrane glycoprotein

Activates extrinsic pathway

IV

Calcium ions (Ca2+)

Plasma

All stages of coagulation

V

Proaccelerin

Plasma protein

Common pathway

VIII

Antihemophilic factor

Plasma protein

Intrinsic pathway; deficiency causes hemophilia A

IX

Plasma thromboplastin component

Plasma protein

Intrinsic pathway; deficiency causes hemophilia B

XIII

Fibrin stabilizing factor

Plasma protein

Cross-links fibrin, stabilizes clot

Additional info:

Other factors (VI, VII, X, XI, XII) also play roles in the cascade.

Plasma proteins

Various steps in intrinsic/extrinsic pathways

Clot Retraction & Fibrinolysis

After a clot forms, it must be stabilized and eventually removed once the vessel is repaired.

  • Clot Retraction:

    • Actin and myosin in platelets contract within 30–60 minutes, pulling on fibrin strands and squeezing serum from the clot.

    • Serum is plasma minus clotting proteins.

    • Draws ruptured blood vessel edges together, aiding healing.

  • Growth Factors:

    • Platelet-derived growth factor (PDGF): Released by platelets, stimulates division of smooth muscle cells and fibroblasts to rebuild vessel wall.

    • Vascular endothelial growth factor (VEGF): Stimulates endothelial cells to multiply and restore lining.

  • Fibrinolysis:

    • Process of clot removal when no longer needed.

    • Key enzyme: Plasmin (precursor: plasminogen, incorporated into clot).

    • Plasminogen activated by tPA (tissue plasminogen activator) released by endothelial cells.

    • Begins within 2 days and continues until clot is dissolved.

  • Equation:

  • Example: Dissolution of a clot after vessel repair.

Factors Limiting Clot Growth or Formation

Mechanisms Limiting Clot Size

Normal clot growth is limited by two main mechanisms: swift removal and dilution of clotting factors, and inhibition of activated clotting factors.

  • Normally flowing blood washes away procoagulants.

  • Thrombin is adsorbed onto fibrin threads, limiting clot size.

  • Antithrombin III (plasma protein) inactivates any escaping thrombin.

  • Protein C (plasma protein) inactivates many intrinsic pathway procoagulants.

  • Heparin (from basophils and mast cells) enhances activity of antithrombin III.

  • Smooth endothelial lining of undamaged vessels prevents undesirable clotting; also, heparin and endothelial-derived NO & prostacyclin inhibit clotting.

Disorders of Hemostasis

Thromboembolic Disorders

These disorders involve undesirable intravascular clotting.

  • Thrombus: Clot that develops and persists in an unbroken vessel; may block circulation and cause tissue death.

  • Embolus: Thrombus freely floating in bloodstream.

  • Embolism: Embolus obstructing a vessel (e.g., pulmonary or cerebral embolism).

  • Risk Factors: Atherosclerosis, inflammation, slow blood flow, or stasis from immobility.

  • Treatment: Drugs such as tPA, streptokinase to dissolve clots via plasmin.

Bleeding Disorders

  • Thrombocytopenia: Deficient number of circulating platelets due to suppression or destruction of bone marrow (malignancy, radiation, drugs). Platelet count <50,000/μl is diagnostic. Treatment is transfusion of concentrated platelets (temporary relief).

  • Impaired Liver Function: Inability to synthesize procoagulants (clotting factors). Causes include vitamin K deficiency, hepatitis, or cirrhosis. Liver disease can also prevent bile production, which is needed to absorb vitamin K.

  • Hemophilia: Hereditary bleeding disorders:

    • Hemophilia A: Most common (77%), due to factor VIII deficiency.

    • Hemophilia B: Due to factor IX deficiency.

Blood Transfusion

Principles and Practice

Blood transfusion is used to replace lost blood volume and restore oxygen-carrying capacity.

  • Cardiovascular system minimizes effects of blood loss by reducing vessel volume and increasing RBC production.

  • Body can compensate for only limited blood loss (15–30% causes pallor/weakness; >30% may be fatal).

  • Volume must be replaced immediately with normal saline or multiple-electrolyte solution (Ringer's solution) to mimic plasma composition.

  • Whole blood transfusion is used for substantial blood loss or thrombocytopenia; packed red cells (PRBC) for anemia.

  • Donor blood is mixed with heparin (Ca2+ chelator, anticoagulant).

  • Blood groups must be determined to prevent fatal transfusion reactions; blood typing determines groups.

Human Blood Groups

ABO Blood Groups

Blood groups are classified based on the presence or absence of agglutinogens (antigens) A and B on the surface of RBCs.

  • Blood may contain anti-A or anti-B antibodies (agglutinins) that act against transfused RBCs with ABO antigens not present on recipient's RBCs.

  • Table: ABO Blood Groups

Blood Type

Antigens on RBCs

Antibodies in Plasma

Can Receive From

Can Donate To

A

A

Anti-B

A, O

A, AB

B

B

Anti-A

B, O

B, AB

AB

A and B

None

A, B, AB, O

AB

O

None

Anti-A, Anti-B

O

A, B, AB, O

Type O is the universal donor; type AB is the universal recipient.

Rh Blood Groups

  • 52 named Rh agglutinogens (Rh factors); C, D, and E are most common.

  • Rh+ indicates presence of D antigen; 85% of North Americans are Rh+.

  • Anti-Rh antibodies are not spontaneously formed in Rh- individuals, but can form after exposure to Rh+ blood.

  • Second exposure to Rh+ blood results in typical transfusion reaction.

  • Rh- mothers carrying Rh+ babies are treated with RhoGAM (anti-Rh serum) to prevent erythroblastosis fetalis (hemolytic disease of the newborn).

Transfusion Reactions

Mechanism and Consequences

Transfusion reactions occur if mismatched blood is infused. The problem arises from recipient's agglutinins (antibodies) acting against donor RBC antigens.

  • Agglutination and clogging of small vessels.

  • RBCs rupture, releasing hemoglobin into bloodstream.

  • Results:

    • Blocked flow to tissues.

    • Reduced oxygen-carrying ability of blood.

    • Hemoglobin precipitates/clogs kidney tubules, possibly causing kidney failure.

  • Symptoms: fever, chills, nausea, vomiting, general toxicity.

  • Prevention: administer alkaline fluids to dilute/dissolve hemoglobin; use diuretics.

  • Autologous transfusion: patient donates own blood prior to surgery.

Blood Typing

Principles and Cross-Matching

  • Donor blood is mixed with antibodies against common agglutinogens; clumping indicates presence of agglutinogen.

  • Blood is typed for ABO and Rh factor.

  • Cross-matching: Typing between specific donor and recipient:

    • Mix recipient's serum with donor RBCs.

    • Mix recipient's RBCs with donor serum.

Review Questions

  • Fibrinolysis is increased by:

    • Activation of thrombin

    • Activation of plasminogen

    • Release of tPA

    • Heparin

  • Which of the following would NOT be a serious concern during a transfusion reaction?

    • Donor antibodies attacking recipient RBCs

    • Clogging of small vessels by agglutinated clumps of RBCs

    • Lysis of donated RBCs

    • Blockage of kidney tubules

Additional info: These notes expand on the original slides by providing definitions, mechanisms, and clinical relevance for each topic, as well as structured tables and equations for clarity.

Pearson Logo

Study Prep